Credit: Avita Medical. The RECELL System is a single-use, autologous cell harvesting device. The Food and Drug Administration (FDA) has approved the RECELL ® System for the treatment of vitiligo. The ...

VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care ...

PERTH, Australia – Avita Medical Ltd. plans to submit its Recell spray-on-skin premarket approval application to the FDA in a few weeks following positive results from its pivotal trial. The ...

AVITA Medical specializes in regenerative medicine and has an innovative device for skin restoration that treats full-thickness skin defects and vitiligo. The RECELL device uses a patient's skin cells ...

VALENCIA, Calif. and MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization ...

Please provide your email address to receive an email when new articles are posted on . The FDA has expanded its approval of the Recell system in combination with meshed autografting to include ...

You may send us your comments on this form by clicking the button below. You will first be asked to supply your name, email address, and location. You must then acknowledge our data protection ...

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical ...

Please provide your email address to receive an email when new articles are posted on . The RECELL system was successful in repigmenting skin in patients with vitiligo, Avita Medical announced in a ...

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform ...